Your browser doesn't support javascript.
loading
Secondary CNS myeloma with remission after systemic CNS-penetrating agents.
Fernandez, Luis G; Oyon, Daniel Eduardo; Gondi, Vinai; Grimm, Sean; Khan, Osaama H.
Afiliación
  • Fernandez LG; Department of Neurosurgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Oyon DE; Department of Neurosurgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Gondi V; Northwestern Medicine Proton Center, Warrenville, Illinois, USA.
  • Grimm S; Rush University Medical Center, Department of Neurological Sciences, Section of Neuro-Oncology, Rush Medical College, Chicago, Illinois, USA.
  • Khan OH; Department of Neurosurgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Neurooncol Adv ; 4(1): vdac106, 2022.
Article en En | MEDLINE | ID: mdl-35892045
ABSTRACT

Background:

CNS myeloma is a rare manifestation of multiple myeloma and is often associated with a dismal prognosis; however, cases are increasing in frequency as overall survival improves for MM. There is currently no standardized treatment for CNS myeloma; however, different chemotherapy and radiotherapy regimens have been described.

Methods:

We had previously reported on the efficacy of proton-based craniospinal irradiation in a patient with CNS myeloma; here we present a patient with a history of extramedullary plasmacytoma, 10 years in remission status post standard systemic chemotherapy, with biopsy-proven CNS myeloma successfully treated with systemic chemotherapy as a first-line treatment.

Results:

The patient achieved clinical and radiographic remission on 2 separate occasions with systemic chemotherapy alone.

Conclusions:

This case demonstrates that systemically administered agents may have activity in CNS myeloma. Further investigations are necessary to establish the optimal combination of agents and treatment schedules.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Neurooncol Adv Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Neurooncol Adv Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
...